Merck’s KEYTRUDA approved to treat PD-L1-positive tumor patients

By Nikita Chaurasia  Date: 2020-08-26

Merck’s KEYTRUDA approved to treat PD-L1-positive tumor patients

U.S.-based multinational pharmaceutical giant Merck & Co. Inc. recently announced that its anti-PD-1 therapy named as KEYTRUDA, has received approvals from Japan Pharmaceuticals as well as from Medical Devices Agency (PMDA).

As per the trusted sources, KEYTRUDA monotherapy is approved to treat patients suffering tumors that are PD-L1-positive and have radically unresectable, recurrent or advanced esophageal squamous cell carcinoma (ESCC).

It is to be noted that KEYTRUDA is an anti-PD-1 therapy that improves body’s immune system and also detects and counters tumor cells. The therapy was initially approved to be used at prescribed dosage of 400 mg every six weeks (Q6W), which is operates as an intravenous infusion over 30 minutes across all adult indications, including combination therapy and KEYTRUDA monotherapy, sources claimed.

Dr. Jonathan Cheng, Vice President of oncology clinical research, Merck Research Laboratories reportedly stated that the company is focusing on improving results for as many cancer patients as possible including those with esophageal squamous cell carcinoma, which is a major reason for cancer-related deaths in Japan.

Cheng further added that by using KEYTRUDA the adult patients will now have the provision of a dosing schedule that helps in decreasing the tumor based on how frequently they are at the clinic for treatment.

Jannie Oosthuizen, President at MSD Japan mentioned that over 90% of esophageal cancers are squamous cell carcinomas. Patients who are suffering from advanced disease face poor prognosis and have a critical requirement of better treatment options, he further claimed.

According to the reliable sources, KEYTRUDA’s approval for 400 mg for every six weeks is based on exposure-response analyses and pharmacokinetic modeling. The interim analysis was reportedly based on the pharmacokinetic modeling data, as well as on safety and efficacy data from KEYNOTE-555 which was gathered from a cohort of patients (Cohort B) who use KEYTRUDA 400 mg Q6W.

Source credits-

https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-two-new-approvals-in-japan/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Universal Music Group leaps to USD 55 billion in stock market debut

Universal Music Group leaps to USD 55 billion in stock market debut

By Nikita Chaurasia

Universal Music Group's stock market debut marked Europe the largest listing this year, with shares surging over a third as investors wager on the potential of music streaming in the long run. The world's largest music label, which represent...

Microsoft offering internships to boost technology skills in Indians

Microsoft offering internships to boost technology skills in Indians

By Nikita Chaurasia

Microsoft Corporation has reportedly launched the new Future Ready Talent internship program to teach technology skills to the Indian youth to make them job-ready. The program is free of cost and can be available for students who have graduated in 2...

PepsiCo to cut plastic use, launch plant-based snacks in green push

PepsiCo to cut plastic use, launch plant-based snacks in green push

By Nikita Chaurasia

As the necessity for actions that tackle climate change intensifies, PepsiCo has announced that it will reduce the use of virgin plastic and expand its business of SodaStream carbonated water to more markets, however, some environmental groups want t...

Google fined USD 177 Mn by South Korea over anti-competitive practices

Google fined USD 177 Mn by South Korea over anti-competitive practices

By Nikita Chaurasia

The fine is considered to be the ninth-biggest by the regulator to date. It was announced when South Korea’s Telecommunications Business Act, popularly known as “anti-Google law” came into effect.  South Korea’s Kore...

England to become the first country to require EV chargers in new homes

England to become the first country to require EV chargers in new homes

By Nikita Chaurasia

Even the commercial establishments will be required to include EV chargers. The news echoes on U.K.’s efforts to achieve net-zero greenhouse gas emissions by 2050. The British government is expected to introduce a new law in 2021 which wi...